A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Intact mass by LC-MS | Compared with theoretical average mass |
| Sequence verification | Enzymatic peptide mapping | Tandem mass spectrometry of fragments |
| Common degradation route | Deamidation and oxidation | Rate increases with pH and temperature |
| Reference material | Lyophilized peptide standard | Stored desiccated below -20 °C |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
== Australian and New Zealand Society for Mass Spectrometry == The major awards from the Australian and New Zealand Society for Mass Spectrometry (ANZSMS) are the ANZSMS Medal, Morrison Medal, Bowel Medal, Michael Guilhaus Research Award and ANZSMS Fellows.
Refrigerators 2 to 3 °C (35 to 38 °F), and not greater than maximum refrigerator temperature at 5 °C (41 °F) Freezer, Reach-in −23 to −15 °C (−10 to +5 °F) Freezer, Walk-in −23 to −18 °C (−10 to 0 °F) Freezer, Ice Cream −29 to −23 °C (−20 to −10 °F)
== Further reading == FDA 21 CFR 113.3 Thermally processed low acid foods packaged in hermetically sealed containers Revision Apr. 2006 Potter, N. N. and Hotchkiss, J. H. Food Science (5th ed). Springer, 1999 Fellows, P. J. Food Processing Technology: Principles and Practice (2nd Edition). Woodhead Pub. 1999 Zeide, Anna (6 March 2018). Canned: The Rise and Fall of Consumer Confidence in the American Food Industry. University of California Press. ISBN 978-0520290686.
== Uses == The most common use of the seed is in the form of lotus seed paste (蓮蓉), which is used extensively in Chinese pastries as well as in Japanese desserts. Dried lotus seeds must be soaked in water overnight prior to use. They can then be added directly to soups and congee or used in other dishes. Fresh lotus seeds are sold in the seed heads of the plant and eaten by breaking the individual seeds out of the cone-shaped head and removing the rubbery shell. Crystallized lotus seeds (蓮子糖), made by drying lotus seeds cooked in syrup, are a common Chinese snack, especially during Chinese new year. Xiangtan or Xianglian lotus seeds, along with Yongfeng chili sauce and Changsha stinky tofu are collectively referred to as "Hunan Sanbao" or Hunan's three treasures. Lotus seeds are also common in the northern part of Colombia, especially in cities like Barranquilla and Cartagena. Locals usually refer to lotus seeds as "martillo." Fresh lotus seeds are sold in street markets and are generally eaten raw by the locals.
Sources: en.wikipedia.org
Once the blood reaches the heart, it moves first into the right atrium, then the right ventricle to be pumped through the lungs for further gas exchange of carbon dioxide waste for oxygen. Oxygenated blood then flows from the lungs through the left atrium to the left ventricle where it is pumped out to the body.
=== Soft-matter and colloidal physics === Mezzenga's research focuses on the physics of self-assembly in polymers, surfactants, proteins, and biological colloids. A central theme of his work is the application of polymer and colloidal physics concepts to complex biological systems, particularly amyloid fibrils and other chiral filamentous materials such as nanocellulose. In 2010, Mezzenga and collaborators developed a statistical and theoretical framework for understanding amyloid fibril aggregation based on the analysis of atomic force microscopy images. This work introduced a polymer-physics-based methodology to study amyloid fibrils that has since been applied broadly to filamentous colloidal systems. In 2018, his group solved a long-standing conundrum in biological liquid crystals by discovering cholesteric phases in amyloid fibrils, which were previously known to form nematic phases but were thought to lack the chiral nematic form.
are the concentrations of the solute's ionic constituents in a saturated solution. The solubility product is derived from and functions like the equilibrium constant of dissociation, though unlike an equilibrium constant it is not dimensionless. If the product of ionic concentrations in a solution exceeds the solubility product, then precipitation occurs.
Sources: en.wikipedia.org
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.
Higher pH and elevated temperature both increase deamidation rates. Holding solutions at low temperature and near-neutral to slightly acidic pH reduces the extent of the reaction.
Removing water slows hydrolysis and aggregation. The dry powder tolerates longer storage intervals than a solution kept at the same temperature.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.